A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)

Exclusion Criteria

• •Pregnant or breastfeeding or intending to become pregnant
• •Participants with active central nervous system (CNS) metastases
• •History of malignancy other than the one under investigation
• •Any unresolved toxicities from prior therapy, i.e., radiotherapy, chemotherapy, targeted therapy or surgical procedure
• •Major surgery or significant traumatic injury \<4 weeks prior to the first CEA-PRIT 2.0 administration (excluding biopsies) or anticipation of the need for major surgery during study treatment
• •Participants have a known confirmed positive test for HIV
• •Positive hepatitis B surface antigen (HBsAg) test, and/or positive total hepatitis B core Ab (HBcAb) test at screening.
• •Positive hepatitis C (HCV) Ab test result at screening
• •Any anticancer treatment or any investigational agent within 4 weeks (or 5 times the half-life, whichever is shorter) prior to C1D1
• •Prior treatment with a CEA-targeted agent or systemic radio therapy